{"id":27464,"date":"2023-06-26T04:15:08","date_gmt":"2023-06-26T08:15:08","guid":{"rendered":"https:\/\/ifintechworld.com\/uncategorized\/novo-nordisk-says-obesity-pill-leads-to-15-weight-loss-availability-to-be-determined\/"},"modified":"2023-06-26T04:15:09","modified_gmt":"2023-06-26T08:15:09","slug":"novo-nordisk-says-obesity-pill-leads-to-15-weight-loss-availability-to-be-determined","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=27464","title":{"rendered":"Novo Nordisk says obesity pill leads to 15% weight loss; availability “to be determined”"},"content":{"rendered":"
\n
\n

\u00a9 Reuters. FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS\/Jacob Gronholt-Pedersen\/File Photo<\/span>
\n<\/i>\n<\/div>\n

By Deena Beasley<\/p>\n

SAN DIEGO (Reuters) -Novo Nordisk on Sunday said a late-stage trial found that a high-dose oral version of its drug semaglutide helped overweight or obese adults lose 15% of their body weight, which is in line with recent results for other experimental obesity pills.<\/p>\n

Novo plans to seek U.S. and European regulatory approval of the high-dose pill later this year, but timing of a market launch is “to be determined,” according to Mico Guevarra, medical director at Novo Nordisk (NYSE:).<\/p>\n

The Danish company has had supply issues and struggled to keep up with soaring U.S. demand for Wegovy and Ozempic, the respective brand names for semaglutide sold as once-weekly injections for treating obesity and diabetes. Wegovy contains 2.4mg of semaglutide.<\/p>\n

The drug, designed to activate hormones that regulate blood sugar, slow stomach emptying and decrease appetite, is part of a new class that has reignited researcher and investor interest in the weight-loss treatment market, which is estimated to reach $100 billion by the end of the decade.<\/p>\n

“We are upping production as much as we can,” Guevarra said in an interview here on the sidelines of the annual meeting of the American Diabetes Association.<\/p>\n

Novo Nordisk already markets an oral semaglutide, under the brand name Rybelsus, for treatment of type 2 diabetes, but its highest dose is 14mg.<\/p>\n

The late-stage trial of 667 obese and overweight adults tested a dose of 50mg, showing that it resulted in average weight loss of 15.1% after 68 weeks, when used alongside diet and physical activity, compared with 2.4% for the placebo group.<\/p>\n

Oral semaglutide, according to the FDA label, needs to be taken in the morning on an empty stomach, 30 minutes before eating, drinking, or using any other oral medication – you are allowed only 4 ounces of plain water. If you eat too soon, the pill is less effective, but if you wait longer than 30 minutes its absorption may be enhanced.<\/p>\n

Other companies are working on obesity pills that don’t have such dietary restrictions, and would in theory also appeal to patients who don’t want to inject themselves weekly.<\/p>\n

Dr. Filip Knopf, professor of endocrinology at Gentofte Hospital, University of Copenhagen and Novo’s study presenter, said his experience is that 20% to 25% of patients would rather have a daily pill instead of a weekly semaglutide injection.<\/p>\n

At the ADA meeting on Friday, results from an Eli Lilly (NYSE:) mid-stage trial showed that the highest dose of its experimental pill orforglipron helped people who were obese or overweight lose 14.7% of their body weight after 36 weeks, and their weight loss had not yet appeared to plateau.<\/p>\n

Novo Nordisk said most patients in its obesity trial reported gastrointestinal side effects from oral semaglutide, including mostly mild-to-moderate nausea, constipation, diarrhea and vomiting.<\/p>\n

Around 13% of patients experienced “altered skin sensation,” which was mostly resolved after several weeks, Dr. Knopf said.<\/p>\n

Results from a separate late-stage trial presented at the ADA meeting showed once-daily oral semglutide, at a dose of up to 50mg, helped patients with type 2 diabetes reduce their blood sugar levels by as much as 2 percentage points.<\/p>\n

Details of both Novo trials were also published in the peer-reviewed Lancet medical journal.<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

\u00a9 Reuters. FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS\/Jacob Gronholt-Pedersen\/File Photo By Deena Beasley SAN DIEGO (Reuters) -Novo Nordisk on Sunday said a late-stage trial found that a high-dose oral version of its drug semaglutide helped overweight or obese adults lose 15% of their body weight, […]<\/p>\n","protected":false},"author":1,"featured_media":27465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[1],"tags":[83],"class_list":["post-27464","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-uncategorized","tag-featured","post_format-post-format-video"],"yoast_head":"\nNovo Nordisk says obesity pill leads to 15% weight loss; availability "to be determined" | iFintechWorld<\/title>\n<meta name=\"description\" content=\"\u00a9 Reuters. FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS\/Jacob Gronholt-Pedersen\/File\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=27464\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk says obesity pill leads to 15% weight loss; availability "to be determined" | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"\u00a9 Reuters. FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS\/Jacob Gronholt-Pedersen\/File\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=27464\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-26T08:15:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-26T08:15:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/06\/EliLilly_800x533_L_1604420191.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=27464#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=27464\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Novo Nordisk says obesity pill leads to 15% weight loss; availability “to be determined”\",\"datePublished\":\"2023-06-26T08:15:08+00:00\",\"dateModified\":\"2023-06-26T08:15:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=27464\"},\"wordCount\":561,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=27464#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=27464\",\"url\":\"https:\/\/ifintechworld.com\/?p=27464\",\"name\":\"Novo Nordisk says obesity pill leads to 15% weight loss; availability \\\"to be determined\\\" | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-06-26T08:15:08+00:00\",\"dateModified\":\"2023-06-26T08:15:09+00:00\",\"description\":\"\u00a9 Reuters. FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS\/Jacob Gronholt-Pedersen\/File\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=27464#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=27464\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=27464#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk says obesity pill leads to 15% weight loss; availability “to be determined”\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novo Nordisk says obesity pill leads to 15% weight loss; availability \"to be determined\" | iFintechWorld","description":"\u00a9 Reuters. FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS\/Jacob Gronholt-Pedersen\/File","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=27464","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk says obesity pill leads to 15% weight loss; availability \"to be determined\" | iFintechWorld","og_description":"\u00a9 Reuters. FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS\/Jacob Gronholt-Pedersen\/File","og_url":"https:\/\/ifintechworld.com\/?p=27464","og_site_name":"iFintechWorld","article_published_time":"2023-06-26T08:15:08+00:00","article_modified_time":"2023-06-26T08:15:09+00:00","og_image":[{"width":800,"height":533,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/06\/EliLilly_800x533_L_1604420191.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=27464#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=27464"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Novo Nordisk says obesity pill leads to 15% weight loss; availability “to be determined”","datePublished":"2023-06-26T08:15:08+00:00","dateModified":"2023-06-26T08:15:09+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=27464"},"wordCount":561,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=27464#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=27464","url":"https:\/\/ifintechworld.com\/?p=27464","name":"Novo Nordisk says obesity pill leads to 15% weight loss; availability \"to be determined\" | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-06-26T08:15:08+00:00","dateModified":"2023-06-26T08:15:09+00:00","description":"\u00a9 Reuters. FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS\/Jacob Gronholt-Pedersen\/File","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=27464#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=27464"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=27464#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk says obesity pill leads to 15% weight loss; availability “to be determined”"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/27464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=27464"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/27464\/revisions"}],"predecessor-version":[{"id":27466,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/27464\/revisions\/27466"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/27465"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=27464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=27464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=27464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}